p16 Protein and Lung Cancer Prognosis
Author Information
Author(s): Huang C-I, Taki T, Higashiyama M, Kohno N, Miyake M
Primary Institution: Kitano Hospital, Tazuke Kofukai Medical Research Institute
Hypothesis
Is p16 protein expression associated with prognosis in squamous cell carcinoma of the lung?
Conclusion
The study found that p16-negative tumors are linked to a poorer prognosis in patients with squamous cell carcinoma of the lung.
Supporting Evidence
- 36.3% of tumors were classified as p16-negative.
- p16-negative tumors in squamous cell carcinomas were significantly more than those in adenocarcinomas.
- The 5-year survival rate of patients with p16-negative tumors was significantly lower than those with p16-positive tumors.
- Survival of patients with p16-negative tumors was significantly worse in early-stage squamous cell carcinoma.
Takeaway
If a lung cancer patient has a p16-negative tumor, they might not live as long as someone with a p16-positive tumor.
Methodology
An immunohistochemical analysis for p16 protein was performed on tumor samples from patients with non-small-cell lung cancer.
Participant Demographics
Patients with non-small-cell lung cancer, specifically squamous cell carcinoma and adenocarcinoma.
Statistical Information
P-Value
P = 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website